IDEAYA Biosciences (IDYA) Amortization of Deferred Charges (2021 - 2026)
IDEAYA Biosciences (IDYA) reported Amortization of Deferred Charges of $455000.0 for Q1 2026, down 14.63% on a YoY basis from $533000.0 in Q1 2025, and down 4.41% sequentially from $476000.0 in Q4 2025.
IDEAYA Biosciences (IDYA) Amortization of Deferred Charges (2021 - 2026) Analysis & Trends
IDEAYA Biosciences (IDYA) has 6 years of Amortization of Deferred Charges data on file, last reported at $455000.0 in Q1 2026.
- For the quarter ending Q1 2026, Amortization of Deferred Charges fell 14.63% year-over-year to $455000.0; the trailing twelve-month figure through Mar 2026 stood at $1.8 million (up 19.88% YoY), and the FY2025 full-year result was $1.9 million, up 30.82% from the prior year.
- Amortization of Deferred Charges eased to $455000.0 in Q1 2026, from $476000.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $533000.0 in Q1 2025 to a low of $71000.0 in Q4 2024.
- A 5-year average of $396529.4 and a median of $386000.0 in 2023 frame the typical range for Amortization of Deferred Charges.
- Across the five-year window, Amortization of Deferred Charges sank 82.03% in 2024 and jumped 570.42% in 2025, its largest moves.
- Tracing IDYA's Amortization of Deferred Charges over 5 years: stood at $364000.0 in 2022, then climbed by 8.52% to $395000.0 in 2023, then slumped by 82.03% to $71000.0 in 2024, then jumped by 570.42% to $476000.0 in 2025, then retreated by 4.41% to $455000.0 in 2026.
- Business Quant data shows IDYA's Amortization of Deferred Charges at $455000.0 in Q1 2026, $476000.0 in Q4 2025, and $369000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - |
| 3 | Akari Therapeutics | 1,045.06 Bn | 1,045.06 Bn | - |
| 4 | BeOne Medicines | 470.64 Bn | 465.84 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.91 Bn | 115.67 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.07 Bn | 61.31 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.77 Bn | 62.77 Bn | - |
| 8 | Argenx Se | 56.21 Bn | 51.02 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.60 Bn | 37.60 Bn | - |
| 10 | IDEAYA Biosciences | 3.22 Bn | 2.55 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 455,000.00 |
| Mar 31, 2026 | 455,000.00 |
| Dec 31, 2025 | 476,000.00 |
| Dec 31, 2025 | 476,000.00 |
| Sep 30, 2025 | 369,000.00 |
| Sep 30, 2025 | 369,000.00 |
| Jun 30, 2025 | 515,000.00 |
| Jun 30, 2025 | 515,000.00 |
| Mar 31, 2025 | 533,000.00 |
| Mar 31, 2025 | 533,000.00 |
| Dec 31, 2024 | 71,000.00 |
| Dec 31, 2024 | 71,000.00 |
| Sep 30, 2024 | 435,000.00 |
| Sep 30, 2024 | 435,000.00 |
| Jun 30, 2024 | 475,000.00 |
| Jun 30, 2024 | 475,000.00 |
| Mar 31, 2024 | 466,000.00 |
| Mar 31, 2024 | 466,000.00 |
| Dec 31, 2023 | 395,000.00 |
| Dec 31, 2023 | 395,000.00 |